FIG 6.

Interferon pretreatment inhibits replication of HAdV in differentiated human enteroid monolayers but not A549 cells. Human enteroid monolayers and A549 cells were pretreated with 1,000 IU/ml of IFN-β (purple) or 500 ng/ml IFN-λ3 (blue) for 24 h or left untreated (black). (A and B) Enteroid monolayers were infected with HAdV-5p at an MOI of 15 (A) or HAdV-41p at an MOI of 6 (B) to achieve similar levels of infection. (C and D) By the same rationale, A549 cells were infected with HAdV-5p at an MOI of 0.5 (C) or HAdV-41p at an MOI of 80 (D). Data are fold changes in viral genomes per cellular genome relative to day 0, and lines connect the mean values ± SD for each time point (n = 3 for each condition). (E) Enteroid monolayers were infected with HAdV-5p at an MOI of 30 (black) or HAdV-41p at an MOI of 200 (pink) or treated with 1,000 IU/ml of IFN-β (purple) for 24 h. Data are the means ± SD of the fold changes in gene expression relative to untreated, uninfected cells (n = 3 for each condition). (F) Enteroid monolayers and A549 cells were treated with 1,000 IU/ml of IFN-β (purple) or 500 ng/ml IFN-λ3 (blue) for 24 h. Data are the means ± SD of the fold changes in gene expression relative to untreated, uninfected cells (n = 3 for each condition). For panels A to D, significance in comparing untreated to IFN treated at each time point: *, P < 0.05; **, P < 0.01; ns, not significant. For panels E and F, data were analyzed using a one-sample t test: *, P < 0.05; **, P < 0.01, ***, P < 0.001; ns, not significant.